Sign up Australia
Proactive Investors - Run By Investors For Investors

FDA committee doesn’t think GSK’s asthma drug can be used to treat COPD as well

Nucala has already been approved to treat asthma patients, but an FDA advisory committee isn't convinced there is enough data to back up GSk's belief that it can help COPD patients as well
man coughing
Advisory committees' recommendations aren't binding, but it would be unusual for the FDA to go against their findings

GlaxoSmithKline PLC (LON:GSK) has been dealt a major blow after a US Food and Drug Administration advisory committee failed to give its backing to the drugs giant’s chronic obstructive pulmonary disorder treatment.

The FTSE 100 group’s Nucala drug has already been approved as a treatment for asthma, but GSK thinks it could also work in patients experiencing a sudden worsening of COPD.

READ: GSK unveils £1.7bn cost-cutting programme as it switches tack on R&D

The committee disagreed though, with 16 of the 19 members voting not to support approval, with the same number agreeing that there was “not substantial evidence of the efficacy”. They did, however, agree that the drug was safe.

As the name suggests, the advisory committee shares its thoughts with FDA regulators, but their recommendations are not binding.

That said, it would be unusual for the FDA to go against the committee, especially when the outcome is so clear.

As part of its report, the committee suggested that GSK go away and get some more data to show which patient population would be more likely to benefit.

GSK still confident

“Having participated in today's advisory committee meeting and heard the recommendation we will continue to work with the FDA to address outstanding questions,” said GSK’s senior vice president of respiratory R&D, Dave Allen.

“We remain confident our data supports mepolizumab as a targeted treatment for patients continuing to experience COPD exacerbations guided by blood eosinophil count.”

It is a blow for Glaxo and its boss, Emma Walmsley, who made respiratory drugs one of the company’s three core therapeutic areas of focus when she took the job almost a year ago.

Nucala generated sales of £141mln in the three months to the end of June. If it was approved for use in COPD, sales could potentially surge, as the disease affects almost 400mln people around the world.

Shares were down 3.7% at 1,485p in late morning trading.

View full GSK profile View Profile

GlaxoSmithKline plc Timeline

Related Articles

cancer cells from taken by an electron microscope
March 13 2018
Sareum has partnered with Sierra Oncology to advance the company's Checkpoint kinase 1 inhibitor
Zelda's Stewart Washer at Proactive's CEO Sessions
November 17 2017
Stewart Washer at Proactive's CEO Sessions this week.
Laboratory
June 21 2018
Genedrive has signed sales agreement with Sysmex Corporation for the distribution of the HCV ID to EMEA and Asia Pacific and with Mumbai- based ARKRAY to distribute the kit in India

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use